WO2003042384A1 - Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation - Google Patents

Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation Download PDF

Info

Publication number
WO2003042384A1
WO2003042384A1 PCT/JP2002/011894 JP0211894W WO03042384A1 WO 2003042384 A1 WO2003042384 A1 WO 2003042384A1 JP 0211894 W JP0211894 W JP 0211894W WO 03042384 A1 WO03042384 A1 WO 03042384A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
differentiation
embryo stem
ectodermal
inducer
Prior art date
Application number
PCT/JP2002/011894
Other languages
English (en)
French (fr)
Inventor
Yoshiki Sasai
Hiroo Iwata
Yoshinobu Murakami
Mitsuo Satoh
Masato Kobori
Keiichi Yano
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to EP02781768A priority Critical patent/EP1452594A4/en
Priority to CA002467258A priority patent/CA2467258A1/en
Priority to US10/495,567 priority patent/US20060281179A1/en
Priority to JP2003544199A priority patent/JP4294482B2/ja
Publication of WO2003042384A1 publication Critical patent/WO2003042384A1/ja
Priority to US12/030,314 priority patent/US20080160617A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
PCT/JP2002/011894 2001-11-15 2002-11-14 Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation WO2003042384A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02781768A EP1452594A4 (en) 2001-11-15 2002-11-14 INDUCTOR FOR DIFFERENTIATING EMBRYOONAL STEM CELLS TO EODODERMAL CELLS, METHOD FOR OBTAINING THEM AND USE THEREOF
CA002467258A CA2467258A1 (en) 2001-11-15 2002-11-14 Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same and use of the same.
US10/495,567 US20060281179A1 (en) 2001-11-15 2002-11-14 Inducer for differentiation of embryo stem cells into ectodermal cells method of obtaining the same and use thereof
JP2003544199A JP4294482B2 (ja) 2001-11-15 2002-11-14 胚性幹細胞から外胚葉系細胞への分化誘導剤、その取得方法及びその用途
US12/030,314 US20080160617A1 (en) 2001-11-15 2008-02-13 Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same, and use of the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001350724 2001-11-15
JP2001-350724 2001-11-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/495,567 A-371-Of-International US20060281179A1 (en) 2001-11-15 2002-11-14 Inducer for differentiation of embryo stem cells into ectodermal cells method of obtaining the same and use thereof
US12/030,314 Division US20080160617A1 (en) 2001-11-15 2008-02-13 Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same, and use of the same

Publications (1)

Publication Number Publication Date
WO2003042384A1 true WO2003042384A1 (fr) 2003-05-22

Family

ID=19163165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011894 WO2003042384A1 (fr) 2001-11-15 2002-11-14 Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation

Country Status (5)

Country Link
US (2) US20060281179A1 (ja)
EP (1) EP1452594A4 (ja)
JP (1) JP4294482B2 (ja)
CA (1) CA2467258A1 (ja)
WO (1) WO2003042384A1 (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
WO2005085426A1 (ja) * 2004-03-04 2005-09-15 Tanabe Seiyaku Co., Ltd. 無フィ−ダ−分化用培地及び霊長類動物胚性幹細胞からの無フィ−ダ−分化方法
WO2006004149A1 (ja) * 2004-07-06 2006-01-12 Kyowa Hakko Kogyo Co., Ltd. 神経細胞の製造方法
JPWO2005080598A1 (ja) * 2004-02-19 2007-08-30 伸弥 山中 体細胞核初期化物質のスクリーニング方法
GB2427876B (en) * 2004-04-09 2009-02-18 Ronald S Goldstein Methods for generating neuronal cells from human embryonic stem cells and uses thereof
WO2010073407A1 (ja) * 2008-12-26 2010-07-01 株式会社大塚製薬工場 幹細胞の分化能の評価方法
US7923246B2 (en) 2004-05-27 2011-04-12 Riken Method of culturing embryonic stem cells with the use of amniotic membrane-origin factor
WO2011074690A1 (en) 2009-12-14 2011-06-23 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
JP2012245007A (ja) * 2004-06-18 2012-12-13 Institute Of Physical & Chemical Research 無血清浮遊培養による胚性幹細胞の神経分化誘導法
CN103097535A (zh) * 2010-07-12 2013-05-08 国立大学法人鸟取大学 利用miRNA导入的新型hiPSC制作法
WO2013140927A1 (ja) 2012-03-21 2013-09-26 国立大学法人京都大学 アルツハイマー病の治療薬および/または予防薬のスクリーニング方法
JP2013188203A (ja) * 2012-02-13 2013-09-26 Nippon Menaade Keshohin Kk 幹細胞から外胚葉系細胞への分化誘導剤
JP5700301B2 (ja) * 2009-06-03 2015-04-15 国立大学法人大阪大学 多能性幹細胞からの神経堤細胞群の分化誘導方法
KR20160045145A (ko) * 2013-08-23 2016-04-26 스미또모 가가꾸 가부시끼가이샤 망막 조직 및 망막 관련 세포의 제조 방법
WO2021220731A1 (ja) * 2020-04-30 2021-11-04 オリエンタル酵母工業株式会社 幹細胞用培地及び幹細胞の培養方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
US7803783B2 (en) 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
US20040265995A1 (en) * 2003-04-01 2004-12-30 Tamara Byk sFRP1 and uses thereof
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
US9085754B2 (en) 2007-03-29 2015-07-21 Technion Research & Development Foundation Limited Isolated population of cells and methods of generating and using same
WO2008127974A1 (en) * 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2020210741A1 (en) * 2019-04-12 2020-10-15 FUJIFILM Irvine Scientific, Inc. Embryo culture media supplement
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756864C5 (de) * 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
MXPA02002624A (es) * 1999-09-13 2002-07-30 Wyeth Corp Composiciones farmaceuticas y metodos de uso de proteinas secretadas relacionadas con la familia "frizzled".
JP4458222B2 (ja) * 2000-05-16 2010-04-28 独立行政法人理化学研究所 胚性幹細胞の外胚葉系細胞への新規な分化誘導法及びその用途
AU2001293586A1 (en) * 2000-09-29 2002-04-08 Vincent Tropepe Primitive neural stem cells and method for differentiation of stem cells to neural cells
US20040014209A1 (en) * 2002-01-23 2004-01-22 Lassar Andrew B. Compositions and methods for modulating cell differentiation
US7390659B2 (en) * 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CZYZ J. ET AL.: "Embryonic stem cell differentiation: the role of extracellular factors", DIFFERENTIATION, vol. 68, no. 4-5, October 2001 (2001-10-01), pages 167 - 174, XP002964708 *
ESTEVE P. ET AL.: "Sfrp1 demarcates the anterior neural plate and promotes eye development in the chick embryo", INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, vol. 45, no. SUPP.1, 2001, pages S65 - S66, XP002964709 *
FINCH P.W. ET AL.: "Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 13, 1997, pages 6770 - 6775, XP002140787 *
KAWASAKI H. ET AL.: "Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity", NEURON, vol. 28, no. 1, 2000, pages 31 - 40, XP002191902 *
KIM A.S. ET AL.: "Wnt receptors and Wnt inhibitors are expressed in gradients in the developing telencephalon", MECH. DEV., vol. 103, no. 1-2, May 2001 (2001-05-01), pages 167 - 172, XP002964710 *
RATTNER A. ET AL.: "A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 7, 1997, pages 2859 - 2863, XP002083363 *
RUSSELL L. ET AL.: "Down-regulated RPS3a/nbl expression during retinoid-induced differentiation of HL-60 cells: a close association with diminished susceptibility to actinomycin D-stimulated apoptosis", CELL. STRUCT. FUNCT., vol. 25, no. 2, 2000, pages 103 - 113, XP002964711 *
See also references of EP1452594A4 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099395A3 (en) * 2003-05-08 2005-03-17 Cellartis Ab A method for the generation of neural progenitor cells
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
US7964401B2 (en) 2004-02-19 2011-06-21 Kyoto University Screening method for somatic cell nuclear reprogramming substance affecting ECAT2 and ECAT3
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
JPWO2005080598A1 (ja) * 2004-02-19 2007-08-30 伸弥 山中 体細胞核初期化物質のスクリーニング方法
WO2005085426A1 (ja) * 2004-03-04 2005-09-15 Tanabe Seiyaku Co., Ltd. 無フィ−ダ−分化用培地及び霊長類動物胚性幹細胞からの無フィ−ダ−分化方法
GB2427876B (en) * 2004-04-09 2009-02-18 Ronald S Goldstein Methods for generating neuronal cells from human embryonic stem cells and uses thereof
US7923246B2 (en) 2004-05-27 2011-04-12 Riken Method of culturing embryonic stem cells with the use of amniotic membrane-origin factor
US8492147B2 (en) 2004-06-18 2013-07-23 Riken Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture
JP2012245007A (ja) * 2004-06-18 2012-12-13 Institute Of Physical & Chemical Research 無血清浮遊培養による胚性幹細胞の神経分化誘導法
WO2006004149A1 (ja) * 2004-07-06 2006-01-12 Kyowa Hakko Kogyo Co., Ltd. 神経細胞の製造方法
WO2010073407A1 (ja) * 2008-12-26 2010-07-01 株式会社大塚製薬工場 幹細胞の分化能の評価方法
JP5700301B2 (ja) * 2009-06-03 2015-04-15 国立大学法人大阪大学 多能性幹細胞からの神経堤細胞群の分化誘導方法
WO2011074690A1 (en) 2009-12-14 2011-06-23 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
CN103097535A (zh) * 2010-07-12 2013-05-08 国立大学法人鸟取大学 利用miRNA导入的新型hiPSC制作法
JP2013188203A (ja) * 2012-02-13 2013-09-26 Nippon Menaade Keshohin Kk 幹細胞から外胚葉系細胞への分化誘導剤
WO2013140927A1 (ja) 2012-03-21 2013-09-26 国立大学法人京都大学 アルツハイマー病の治療薬および/または予防薬のスクリーニング方法
KR20160045145A (ko) * 2013-08-23 2016-04-26 스미또모 가가꾸 가부시끼가이샤 망막 조직 및 망막 관련 세포의 제조 방법
KR102278978B1 (ko) 2013-08-23 2021-07-19 스미또모 가가꾸 가부시끼가이샤 망막 조직 및 망막 관련 세포의 제조 방법
US11473056B2 (en) 2013-08-23 2022-10-18 Sumitomo Chemical Company, Limited Method for producing retinal tissue and retina-related cells
WO2021220731A1 (ja) * 2020-04-30 2021-11-04 オリエンタル酵母工業株式会社 幹細胞用培地及び幹細胞の培養方法

Also Published As

Publication number Publication date
US20080160617A1 (en) 2008-07-03
CA2467258A1 (en) 2003-05-22
JP4294482B2 (ja) 2009-07-15
EP1452594A1 (en) 2004-09-01
JPWO2003042384A1 (ja) 2005-03-10
EP1452594A4 (en) 2007-01-10
US20060281179A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2003042384A1 (fr) Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation
WO2004008100A3 (en) Methods and media for controlling sialylation of proteins produced by mammalian cells
WO2002086107A3 (en) A method for differentiating stem cells into insulin-producing cells
WO2003041496A1 (fr) Animal transgenique
WO2004080175A3 (en) Scaffold for cell growth and differentiation
WO2004000006A3 (en) Method of transforming soybean
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
WO2007063545A3 (en) Methods of improving stem cell homing and engraftment
WO2003012082A3 (en) Method for modulating stem cell differentiation using stem loop rna
AU2003238717A1 (en) POLYPEPTIDES HAVING Alpha- H-Alpha-AMINO ACID AMIDE RACEMASE ACTIVITY AND NUCLEIC ACIDS ENCODING THE SAME
EP1640449A4 (en) CELL DIFFERENTIATION INHIBITOR AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTIVATED CELL LINE
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
EP1535993A4 (en) METHOD FOR TRANSFERRING A BIOMOLECULE USING A VIRAL ENVELOPE AND COMPOSITION AND SYSTEM THEREOF
ATE335808T1 (de) Herstellung von zellsuspensionen
WO2004000993A3 (en) Oxytocin as cardiomyogenesis inducer and uses thereof
WO2002076386A3 (en) Method of inducing proliferation of retinal stem cells
WO2007070390A3 (en) Method for prolonging activity of autodegradable enzymes
PL354747A1 (en) Modified ubiquitin regulatory system
WO2001040443A3 (fr) Methode de production de cellules animales adherentes
WO2005046581A3 (en) P18 in stem cell manipulations
WO2001073075A3 (en) Muskmelon cucumis melo hydroperoxide lyase and uses thereof
WO2006088747A3 (en) Serum-free reagents for the isolation, cultivation, and cryopreservation of postnatal pluripotent epiblast-like stem cells
WO2004009028A3 (en) Method and composition for treating and preventing influenza infection and symptoms thereof
WO2005113750A3 (de) Verfahren und vorrichtungen zum kultivieren von stammzellen
WO2003079969A3 (en) Compositions and methods for treating and preventing necrosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2467258

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003544199

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006281179

Country of ref document: US

Ref document number: 10495567

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002349636

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002781768

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002781768

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10495567

Country of ref document: US